Author/Authors :
M. Raymond V. Finlay، نويسنده , , David G. Acton، نويسنده , , David M. Andrews، نويسنده , , Andrew J. Barker، نويسنده , , Michael Dennis، نويسنده , , Eric Fisher، نويسنده , , Mark A. Graham، نويسنده , , Clive P. Green، نويسنده , , David W. Heaton، نويسنده , , Galith Karoutchi، نويسنده , , Sarah A. Loddick، نويسنده , , Remy Morgentin، نويسنده , , J. Andrew Roberts، نويسنده , , Julie A. Tucker and Ric، نويسنده , , Hazel M. Weir، نويسنده ,
Abstract :
A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The compounds exhibit excellent physiochemical properties and a novel binding mode, whereby a bridging interaction via a water molecule with Asp 86 of CDK2, leads to selectivity for the CDK family of enzymes over other kinases. Piperazines 2e and 2i were subsequently shown to inhibit tumour growth when dosed orally in a nude mouse xenograft study. Additional chemical series that exploit this unexpected interaction with Asp 86 are also described.
Keywords :
kinase , cancer , inhibitor , CDK
